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BACKGROUND:The aim of this study was to characterise the familial association of pancreatic cancer with other malignancies.
METHODS: Relative risks (RRs) of pancreatic cancer according to family history of cancer were calculated using the updated Swedish
Family-Cancer Database, which includes over 11.5 million individuals. Estimates were based on Poisson regression. RRs of tumours
for individuals with a parental history of pancreatic cancer were also estimated.
RESULTS: The risk of pancreatic cancer was elevated in individuals with a parental history of cancers of the liver (RR 1.41; 95%
CI 1.10–1.81), kidney (RR 1.37; 95% CI 1.06–1.76), lung (RR 1.50; 95% CI 1.27–1.79) and larynx (RR 1.98; 95% CI 1.19–3.28).
Associations were also found between parental history of pancreatic cancer and cancers of the small intestine, colon, breast, lung,
testis and cervix in offspring. There was an increased risk of pancreatic cancer associated with early-onset breast cancer in siblings.
CONCLUSION:Pancreatic cancer aggregates in families with several types of cancer. Smoking may contribute to the familial aggregation
of pancreatic and lung tumours, and the familial clustering of pancreatic and breast cancer could be partially explained by inherited
mutations in the BRCA2 gene.
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Pancreatic cancer is the fourth most common cause of death from
cancer in Sweden (Hemminki and Li, 2003a; Linder et al, 2007).
Prognosis for patients with this disease is very poor: the median
survival time is 6 months and the 5-year survival rate is below 10%
(Rulyak and Brentnall, 2004; Ghaneh et al, 2007; Linder et al,
2007). Early treatment of pancreatic cancer increases the likelihood
of survival (Greenhalf and Neoptolemos, 2006). However, most
patients are diagnosed at an advanced stage (Klein et al, 2002;
Greer et al, 2007). Studying the familial clustering of pancreatic
cancer with non-pancreatic malignancies meets two objectives: it
provides information for cancer risk assessment in genetic
counselling and provides clues with regard to the aetiology of
the disease.
Around 4% of patients diagnosed with pancreatic cancer have
parents or siblings who are also affected by pancreatic cancer
(Hemminki et al, 2008). It has been estimated that up to 20% of the
familial clustering of pancreatic cancer can be attributed to
syndromes such as hereditary non-polyposis colon cancer
(HNPCC), familial adenomatous polyposis and familial atypical
multiple mole melanoma syndrome (Klein et al, 2001; Jaffee et al,
2002). The corresponding genes associated with these disorders are
mismatch repair genes, APC and CDKN2A (Klein et al, 2001;
Lynch and de la Chapelle, 2003). Other reported risk factors for the
disease are tobacco smoking, obesity and diet rich in calories and
meat (Coughlin et al, 2000; Chiu et al, 2001; Michaud et al, 2001;
MacLeod and Chowdhury, 2006; Ghaneh et al, 2007).
The present population-based study used the Swedish Family-
Cancer Database. An important advantage of the database is that
information on familial relationships and cancers comes from
registered sources of practically complete coverage, thus offering
unique possibilities for precise and unbiased assessment. The risks
of pancreatic cancer were estimated according to family history of
the most prevalent types of cancer. Risks of non-pancreatic
malignancies for individuals with a family history of pancreatic
cancer were also calculated. The database has been used previously
to assess the association of pancreatic cancer with parental history
of cancers from 1961 to 1998 (Hemminki and Li, 2003a). The database
was updated in 2006 and now includes over 1.2 million tumours
diagnosed between 1958 and 2004. Compared with the previous
version, the number of pancreatic cancer patients with a parental
history of the disease increased from 34 to 84 patients. Using
the updated database, we explored the risk of pancreatic cancer
according to sibling history of cancer as well. As early age of
onset has been a reported characteristic of hereditary cancer,
we additionally calculated the relative risks of pancreatic cancer
according to the parental/sibling age of diagnosis of cancer
(Krainer et al, 1997; Raimondi et al, 2007).
PATIENTS AND METHODS
Data on the incidence of pancreatic cancer between 1961 and 2004
in Sweden were derived from the Nordcan Database (Engholm
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set al, 2008). Relative risks of pancreatic and other cancers were
calculated using the updated Swedish Family-Cancer Database.
The population-based Swedish Family-Cancer Database was
created by linking the Multigeneration Register at Statistics
Sweden to the Swedish Cancer Registry (Hemminki et al, 2001).
The Multigeneration Register includes individuals born in Sweden
after 1931 and their biological parents. The Swedish Cancer
Registry is based on compulsory reports about patients provided
by pathologists and cytologists, who report every cancer diagnosis
on surgically removed tissues, biopsies, cytological specimens,
bone marrow aspirates and autopsies (Center for Epidemiology,
2004). The latest update of the database comprises more than 11.5
million individuals. Data on patients with cancer were retrieved
from the Swedish Cancer Registry from 1961 to 2004. The coverage
of the database is practically complete; however, some familial
links are missing from offspring who were born before 1941 and
who died between 1960 and 1997. The effect of the missing data is a
reduced number of mortal cancers among offspring. This is
unlikely to cause bias to familial studies because familial and
sporadic cases would be reduced proportionately (Hemminki et al,
1998; Hemminki and Vaittinen, 1999). This study relies on
individuals who had information available about both parents.
Family history was restricted to first-degree relatives, that is, to
parents and siblings.
Follow-up started from the date of birth, immigration or from 1
January 1961, whichever occurred last. Follow-up ended on the date
of diagnosis of first cancer, on death, emigration or on the closing
date of the study (31 December 2004), whichever came first. Cases of
cancer and person-years were classified according to gender, family
history of cancer, calendar year, age, socioeconomic status and
geographical region. The distribution of the number of cases in each
group was modelled by Poisson regression. We controlled for family
history of cancer, gender, calendar year, age, socioeconomic status
and geographical region in all models. In addition, dichotomous
variables were created according to parental/sibling age of diagnosis
with cancer (0–55; 56–71; 72 or older).
The Genmod procedure of SAS software was used for the analysis
(SAS Version 9.1; SAS Institute, Cary, NC, USA). Standard Poisson
regression assumes independent observations. To account for the
possible overdispersion because of a clustered family structure, s.e.
can be adjusted using Pearson’s w
2-test, divided by degrees of
freedom. The adjustment results in slightly wider confidence
intervals. For example, the relative risk (RR) of pancreatic cancer
for individuals with a family history of pancreatic cancer was 2.11
(95% CI¼1.67–2.66) after adjustment and 2.11 (95%¼CI 1.73–
2.57) without adjustment. However, this procedure may be
particularly sensitive to outlying observations that are expected in
our large data set. Therefore, we show in this article unadjusted CIs
and point to the possibility of conservative limits due to familial
dependence. The tables in this study show only cancer sites with
significant results or with at least 30 affected parent–offspring pairs.
Risk of pancreatic cancer in hereditary pancreatitis was analysed
by identifying hospitalised cases of chronic pancreatitis through the
Swedish Hospital Discharge Register, containing all hospitalisations
in Sweden between 1964 and 2007, but with a nationwide coverage
only since 1987 (for description, see (Hemminki et al, 2009)). Familial
pancreatitis was defined when at least two family members were
hospitalised with this disease. Pancreatic cancers in any family
members were scored through the Cancer Registry. Similarly, patients
hospitalised for cystic fibrosis were identified and their subsequent
pancreatic cancers were retrieved from the Cancer Registry.
RESULTS
Age-standardised incidence of pancreatic cancer in Sweden in the
period 1961–2004 is shown in Figure 1. The incidence of
pancreatic cancer in this period is stable, except from a spike in
the early 1970s among men. The proportion of pancreatic cancer
patients with a parent or sibling affected by the disease was 3.66%
(N¼103).
Table 1 provides the results of a multivariate Poisson regression
that included a dichotomous variable for family history of
pancreatic cancer diagnosed at any age, in addition to gender,
calendar year, age, socioeconomic status and geographical region:
women were at a slightly lower risk of pancreatic cancer compared
with men (RR 0.86; 95% CI 0.75–0.97). As expected, age was found
to be associated with the risk of developing pancreatic cancer. The
risk of pancreatic cancer was increased among individuals with a
family history of the malignancy (RR 2.11; 95% CI 1.73–2.57).
Individuals with a parent diagnosed with pancreatic cancer are at
an increased risk of developing pancreatic cancer (RR 1.93; 95% CI
1.55–2.40) (Table 2). There was an increased risk of pancreatic
cancer among the offspring of patients with cancers of the liver
(RR 1.41; 95% CI 1.10–1.81), larynx (RR 1.98; 95% CI 1.19–3.28),
lungs (RR 1.50; 95% CI 1.27–1.79) and kidneys (RR 1.37; 95% CI
1.06–1.76).
In contrast, we also examined the risk of tumours in the
offspring of pancreatic cancer patients (Table 3). There was an
increased risk of cancer of the small intestine (RR 1.62; 95% CI
1.02–2.55) and colon (RR 1.28; 95% CI 1.10–1.48) among those
with a parental history of pancreatic cancer. Parental pancreatic
cancer was associated with an increased risk of melanoma in the
offspring (RR 1.25; 95% CI 1.10–1.42). The offspring of patients
with pancreatic cancer were at a higher risk of cancers of the liver
(RR 1.52; 95% CI 1.17–1.98), lung (RR 1.18; 95% CI 1.02–1.36)
and the breast (RR 1.21; 95% CI 1.13–1.31). Women with a
parental history of pancreatic cancer had an increased risk of
developing cervical cancer (RR 1.44; 95% CI 1.18–1.76). Sons of
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Figure 1 Age-standardised incidence of pancreatic cancer/100000
individuals in Sweden in 1961–2004 (adjusted to world standard
population).
Table 1 Relative risk of pancreatic cancer according to sex, age and
family history of pancreatic cancer
Covariate Level N RR (95% CI)
Gender Females 1314 0.86 (0.75–0.97)
Males 1502 1.00 (ref.)
Age of diagnosis (years) Before 50 507 0.03 (0.03–0.04)
50–54 502 0.32 (0.28–0.35)
55–59 751 0.60 (0.55–0.66)
60 and above 1056 1.00 (ref)
Family history Yes 103 2.11 (1.73–2.57)
of pancreatic cancer No 2713 1.00 (ref.)
Bold signifies Po0.05.
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spatients with pancreatic cancer had an elevated risk of cancers of
the testis (RR 1.35; 95% CI 1.06–1.73) and other male genital
organs (RR 1.88; 95% CI 1.06–3.34). The risk of Hodgkin’s disease
was elevated among those individuals whose parent was diagnosed
with pancreatic cancer after the age of 71 years (RR 1.67; 95% CI
1.04–2.69). Parental history of pancreatic cancer after the age of 71
years increased the risk of endometrial cancer in women (RR 1.33;
95% CI 1.04–1.72).
Sibling history of pancreatic cancer tripled the risk of pancreatic
cancer (RR 3.26; 95% CI 2.07–5.12) (Table 4). The risk of
pancreatic cancer was elevated among siblings of patients with
cancers of the oesophagus (RR 3.39; 95% CI 1.69–6.79) and liver
(RR 2.07; 95% CI 1.15–3.75). Almost all siblings were diagnosed
with cancer of the oesophagus or of the liver after the age of 55
years. Pancreatic cancer risk was elevated among those whose
sibling had cancer of the connective tissue (RR 3.12; 95% CI 1.62–
6.00). The risk of pancreatic cancer was increased among individ-
uals with a sibling history of male genital organs (RR 3.57; 95% CI
1.15–11.1). The risk of pancreatic cancer was elevated among
those whose sibling had melanoma of the eye (RR 3.26; 95% CI
1.05–10.1). An individual’s pancreatic cancer risk was modified
by his/her sibling’s age of diagnosis of cancers at three sites.
An increased risk of pancreatic cancer was noted only for those
whose sibling was diagnosed before the age of 56 years with
cancers of the breast (RR 1.37; 95% CI 1.06–1.77) and lung
(RR 1.74; 95% CI 1.01–3.00). Similarly, there was an increased risk
of pancreatic cancer among those whose brother had prostate
cancer before the age of 56 years (RR 2.36; 95% CI 1.23–4.54).
To establish the possible association of familial pancreatic
cancer with known syndromes that show pancreatic cancer,
patients were identified from the Hospital Discharge Register. A
total of 1916 patients with chronic pancreatitis were identified and
66 of them were familial cases; 25 pancreatic cancer cases were
identified among all patients but none belonged to the familial
pancreatitis group. A total of 774 cystic fibrosis patients were
identified in the Hospital Discharge Register but none was
diagnosed with pancreatic cancer.
DISCUSSION
Studying the familial aggregation of pancreatic cancer offers a
unique opportunity to advance our understanding of pancreatic
cancer development. An advantage of this study was that data on
familial relationships were obtained from registered sources and
tumour diagnoses were histologically confirmed, excluding any
type of recall bias. The updated Swedish Family-Cancer Database
permitted us to study pancreatic cancer risk not only according to
parental but also according to sibling history of cancer.
The small estimated proportion of familial cases of pancreatic
cancer in our dataset (3.66%) was in accordance with earlier
calculations (Hemminki et al, 2008).
Familial aggregation of cancer can be because of a shared
genetic background or because of common environmental
exposures within families. Risks for concordant and discordant
cancers in spouses have been estimated elsewhere to quantify
cancer risks from the shared environment (Hemminki and Jiang,
2002). That study was restricted to spouses who had one or more
children in common and who lived together for at least 15 years
after the first child’s birth. The analysis showed no increased
Table 2 Relative risks of pancreatic cancer (RR) for the offspring of individuals affected by cancer
Parental age of diagnosis with cancer
Any age 0–55 56–71 72+
Parental cancer site N RR (95% CI) N RR (95% CI) N RR (95% CI) N RR (95% CI)
Upper aerodigestive tract 25 1.06 (0.71–1.56) 5 1.79 (0.75–4.31) 13 1.15 (0.67–1.99) 7 0.74 (0.35–1.55)
Oesophagus 11 0.98 (0.54–1.77) 5 0.98 (0.41–2.35) 5 0.93 (0.39–2.24)
Stomach 82 1.09 (0.87–1.36) 8 1.25 (0.63–2.51) 36 1.09 (0.78–1.51) 38 1.08 (0.78–1.48)
Small intestine 3 0.53 (0.17–1.64)
Colon 109 1.03 (0.85–1.25) 13 1.62 (0.94–2.80) 42 1.02 (0.75–1.39) 54 0.97 (0.74–1.27)
Rectum 73 1.23 (0.97–1.55) 6 1.20 (0.54–2.67) 28 1.13 (0.78–1.65) 39 1.33 (0.97–1.82)
Liver 63 1.41 (1.10–1.81) 4 1.67 (0.63–4.45) 13 0.72 (0.42–1.24) 46 1.90 (1.42–2.55)
Pancreas 84 1.93 (1.55–2.40) 10 3.32 (1.78–6.18) 41 2.19 (1.61–2.98) 33 1.54 (1.09–2.17)
Larynx 15 1.98 (1.19–3.28) 8 1.96 (0.98–3.92) 6 2.41 (1.08–5.37)
Lung 136 1.50 (1.27–1.79) 20 2.52 (1.62–3.92) 56 1.26 (0.96–1.64) 60 1.58 (1.22–2.04)
Breast 156 1.12 (0.95–1.32) 27 1.02 (0.70–1.49) 76 1.25 (1.00–1.58) 53 1.05 (0.80–1.37)
Cervix uteri 18 0.68 (0.43–1.08) 9 0.71 (0.37–1.37) 8 0.81 (0.41–1.63)
Endometrium 41 1.19 (0.87–1.62) 10 1.61(0.86–2.99) 21 1.27 (0.82–1.95) 10 0.88 (0.47–1.64)
Ovary 22 0.72 (0.47–1.09) 6 0.94 (0.42–2.08) 10 0.65 (0.35–1.21) 6 0.68 (0.31–1.52)
Prostate 197 1.02 (0.88–1.18) 8 1.08 (0.54–2.17) 65 0.99 (0.77–1.26) 124 1.03 (0.86–1.23)
Testis 2 1.16 (0.29–4.64)
Other male genital organs 3 1.30 (0.42–4.02)
Kidney 60 1.37 (1.06–1.76) 7 1.36 (0.65–2.85) 27 1.27 (0.87–1.86) 26 1.51 (1.03–2.22)
Urinary organs 66 1.03 (0.81–1.32) 4 0.82 (0.31–2.18) 27 1.02 (0.70–1.49) 35 1.09 (0.78–1.52)
Melanoma 34 1.30 (0.92–1.82) 9 1.66 (0.86–3.21) 16 1.54 (0.94–2.52) 9 0.89 (0.46–1.70)
Squamous cell skin 47 0.88 (0.66–1.18) 2 0.77 (0.19–3.08) 13 0.92 (0.53–1.59) 32 0.88 (0.62–1.24)
Eye 2 0.61 (0.15–2.43)
Nervous system 33 1.00 (0.71–1.41) 5 0.70 (0.29–1.69) 20 1.21 (0.78–1.87) 8 0.89 (0.45–1.79)
thyroid gland 15 1.53 (0.92–2.54) 4 1.77 (0.67–4.73) 8 1.82 (0.91–3.65) 3 0.98 (0.32–3.03)
Endocrine glands 28 1.41 (0.97–2.05) 6 1.87 (0.84–4.17) 12 1.27 (0.72–2.23) 10 1.44 (0.77–2.68)
Connective tissue 10 1.20 (0.64–2.23) 2 1.57 (0.39–6.27) 6 1.80 (0.81–4.02) 2 0.54 (0.14–2.17)
Non-Hodgkin’s lymphoma 31 0.86 (0.60–1.23) 3 0.84 (0.27–2.61) 12 0.83 (0.47–1.46) 16 0.89 (0.55–1.46)
Hodgkin’s disease 8 1.33 (0.66–2.66) 3 1.06 (0.34–3.29) 4 2.27 (0.85–6.06)
Leukaemia 34 0.88 (0.63–1.24) 4 0.98 (0.37–2.61) 11 0.67 (0.37–1.22) 19 1.06 (0.68–1.67)
Bold signifies Po0.05.
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spancreatic cancer risk among spouses of pancreatic cancer patients
(Hemminki and Jiang, 2002). In agreement with previous studies,
our analysis confirmed an increased risk of pancreatic cancer
among individuals with a family history of pancreatic cancer
(Hemminki and Li, 2003a; McWilliams et al, 2005). The fact that
the risk of pancreatic cancer associated with sibling history was
higher might indicate a recessive mode of inheritance. The greater
risk in siblings than in offspring could also suggest that anti-
cipation is operative in familial pancreatic cancer (Lerch, 2006;
McFaul et al, 2006).
Previous studies reported an increased risk of pancreatic cancer
in the offspring of patients with cancers of the pancreas, rectum
and lungs (Hemminki and Li, 2003a). Associations between
pancreatic cancer and cancers of the colon, breast and liver have
also been described (Hemminki and Li, 2003b; Hemminki and
Chen, 2004; Lorenzo Bermejo and Hemminki, 2004). Our analysis
confirmed the above-mentioned findings and showed that cancers
of the cervix, testis and of other male genital organs may be
associated with pancreatic cancer; however, additional studies are
necessary to confirm these associations.
Cancer syndromes and mutations could contribute to the
observed aggregation of pancreatic cancer with other cancers.
Individuals with HNPCC have an increased risk of carcinoma of
the endometrium, ovary, stomach, small bowel, pancreas and brain
(Lynch and de la Chapelle, 2003). Association of pancreatic cancer
in our study with colon and small intestinal cancers may indicate
the presence of HNPCC in some families in the Swedish Family-
Cancer Database (Lynch and de la Chapelle, 2003). Inherited
mutations of the CDKN2A tumour suppressor gene have been
reported in pancreatic cancer patients with a family history of
melanoma (Goldstein et al, 1995; Vasen et al, 2000). The BRCA2
gene might also be involved in the observed aggregations of
pancreatic cancer with other cancers (for example, breast,
prostate). Mutations of BRCA2 were implicated in cancers of the
pancreas (Thorlacius et al, 1996; Couch et al, 2007) and breast
(FitzGerald et al, 1996; Gayther and Ponder, 1997). Germ line
mutations of BRCA2 were also linked to early-onset prostate
cancer (Agalliu et al, 2007). Our analysis showed that early age of
onset of sibling breast cancer increased an individual’s risk of
pancreatic cancer. We also found that there was an increased risk
of pancreatic cancer associated with early-onset prostate cancer in
siblings. The risk of breast cancer was also increased among
offspring of pancreatic cancer patients.
An approximately twofold increased risk for pancreatic cancer
was observed among ever smokers compared with non-smokers
(Fuchs et al, 1996; Muscat et al, 1997; Hassan et al, 2007). Smoking
is also a major risk factor of lung, oesophagus and kidney cancers
(Chiu et al, 2001; Ghaneh et al, 2007). In accordance with previous
studies, we found that pancreatic cancer was associated with other
tobacco-related cancers (oesophagus, lung and kidney) (Hemmin-
ki and Li, 2003a; Shen et al, 2006). In addition, reverse analysis
showed that early onset of pancreatic cancer in parents was
positively associated with the risk of lung cancer in offspring.
Hereditary pancreatitis and cystic fibrosis are known but rare
risk factors of pancreatic cancer (Howes et al, 2004; Maisonneuve
et al, 2007; Rebours et al, 2009). However, using the nation-wide
Hospital Discharge Register for case identification, no pancreatic
cancer could be linked to these causes. In a European study on 418
patients from hereditary pancreatitis families, 26 (6%) were
diagnosed with pancreatic cancer but close to 70% of the cancer
Table 3 Relative risk of tumours (RR) for the offspring of individuals affected by pancreatic cancer
Parental age of diagnosis with pancreatic cancer
Any 0–55 56–71 72+
Offspring cancer site N RR (95% CI) N RR (95% CI) N RR (95% CI) N RR (95% CI)
Upper aerodigestive tract 60 1.25 (0.97–1.61) 6 1.41 (0.63–3.15) 35 1.63 (1.16–2.27) 19 0.87 (0.55–1.36)
Salivary glands 18 2.06 (1.29–3.29) 9 2.17 (1.13–4.20) 9 2.44 (1.26–4.71)
Oesophagus 21 1.16 (0.75–1.79) 2 1.63 (0.41–6.52) 15 1.90 (1.14–3.16) 4 0.45 (0.17–1.19)
Stomach 47 1.13 (0.85–1.51) 25 1.37 (0.93–2.03) 21 1.05 (0.69–1.63)
Small intestine 19 1.62 (1.02–2.55) 5 0.95 (0.39–2.28) 13 2.38 (1.38–4.13)
Colon 182 1.28 (1.10–1.48) 15 1.34 (0.81–2.23) 79 1.27 (1.01–1.58) 88 1.29 (1.04–1.60)
Rectum 98 1.11 (0.91–1.36) 5 0.79 (0.33–1.89) 51 1.33 (1.01–1.75) 42 0.98 (0.72–1.32)
Liver 58 1.52 (1.17–1.98) 5 1.80 (0.75–4.33) 28 1.69 (1.16–2.46) 25 1.34 (0.90–1.99)
Pancreas 84 1.93 (1.55–2.40) 10 3.32 (1.78–6.18) 41 2.19 (1.61–2.98) 33 1.54 (1.09–2.17)
Larynx 15 1.26 (0.75–2.10) 7 1.32 (0.63–2.79) 7 1.22 (0.58–2.58)
Lung 191 1.18 (1.02–1.36) 19 1.66 (1.06–2.61) 82 1.17 (0.94–1.45) 90 1.13 (0.92–1.39)
Breast 726 1.21 (1.13–1.31) 75 1.32 (1.05–1.66) 361 1.33 (1.20–1.48) 290 1.09 (0.97–1.22)
Cervix uteri 101 1.44 (1.18–1.76) 13 1.35 (0.78–2.33) 55 1.61 (1.24–2.10) 33 1.28 (0.91–1.81)
Endometrium 107 1.18 (0.97–1.42) 5 0.80 (0.33–1.91) 41 1.05 (0.77–1.43) 61 1.33 (1.04–1.72)
Ovary 104 1.20 (0.99–1.45) 11 1.30 (0.72–2.35) 51 1.30 (0.99–1.71) 42 1.09 (0.80–1.48)
Prostate 316 1.01 (0.90–1.12) 11 0.67 (0.37–1.20) 151 1.12 (0.96–1.32) 154 0.94 (0.80–1.10)
Testis 65 1.35 (1.06–1.73) 8 1.04 (0.52–2.07) 38 1.57 (1.14–2.16) 19 1.22 (0.78–1.92)
Other male genital organs 12 1.88 (1.06–3.34) 5 1.70 (0.71–4.12) 7 2.43 (1.15–5.13)
Kidney 67 0.98 (0.77–1.25) 31 1.02 (0.72–1.45) 35 1.09 (0.78–1.51)
Urinary organs 110 1.11 (0.92–1.34) 8 1.09 (0.55–2.19) 47 1.08 (0.81–1.44) 55 1.15 (0.89–1.51)
Melanoma 241 1.25 (1.10–1.42) 32 1.47 (1.04–2.08) 133 1.47 (1.24–1.74) 76 0.96 (0.77–1.21)
Squamous cell skin 65 1.06 (0.83–1.35) 5 1.02 (0.43–2.46) 27 0.99 (0.68–1.45) 33 1.13 (0.81–1.60)
Eye 5 0.78 (0.32–1.88) 2 0.68 (0.17–2.71) 3 1.06 (0.34–3.29)
Nervous System 151 0.98 (0.84–1.15) 21 1.13 (0.74–1.74) 61 0.84 (0.66–1.09) 69 1.10 (0.81–1.40)
Thyroid gland 35 0.83 (0.59–1.16) 8 1.49 (0.74–2.97) 14 0.69 (0.41–1.17) 13 0.80 (0.46–1.38)
Endocrine glands 93 1.28 (1.04–1.57) 15 1.96 (1.18–3.26) 40 1.19 (0.87–1.62) 38 1.22 (0.89–1.68)
Connective tissue 25 0.99 (0.67–1.48) 3 0.99 (0.32–3.06) 9 0.76 (0.39–1.46) 13 1.28 (0.74–2.21)
Non-Hodgkin’s lymphoma 115 1.14 (0.94–1.37) 14 1.46 (0.87–2.47) 51 1.11 (0.84–1.46) 50 1.10 (0.83–1.45)
Hodgkin’s disease 34 1.16 (0.82–1.62) 6 1.35 (0.61–3.02) 11 0.77 (0.43–1.39) 17 1.67 (1.04–2.69)
Leukaemia 88 1.03 (0.84–1.27) 10 1.03 (0.56–1.92) 45 1.13 (0.85–1.52) 33 0.90 (0.64–1.27)
Bold signifies Po0.05.
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scases were diagnosed 50 or more years after the diagnosis of
pancreatitis (Howes et al, 2004). However, our maximal follow-up
time was 43 years, of which only 21 years were with a full national
coverage, decreasing the chances of finding a relationship between
the two diseases. Pancreatic cancer is a rare complication after
cystic fibrosis and the risk of estimation has been based on
international case collections (Maisonneuve et al, 2007).
A potential limitation of our study was the unavailability of
information on other potential risk factors of pancreatic cancer
such as tobacco smoking, alcohol consumption and diet. It is
important to note that some of the significant associations could
be attributed to chance as well. Our investigation was also limited
by the small number of tumours at some locations. The problem
could be alleviated when future updates of the Swedish Family-
Cancer Database are available.
The present results on the aggregation of pancreatic cancer with
other cancers in Swedish families suggest that pancreatic cancer
shares a genetic and/or environmental aetiology with cancer at
several sites. The results of this study demonstrated a familial
association of pancreatic tumours with cancers of the lung, liver
and kidney. An association was also found between pancreatic
cancer in parents and melanoma in offspring. Individuals with a
parental history of pancreatic cancer showed an increased risk of
small intestine, colon, lung, breast, testicular and cervical cancers.
There was an elevated risk of pancreatic cancer among those
whose sibling had lung cancer before the age of 56 years. Some of
the observed associations might be related to smoking and
mutations in genes such as BRCA2.
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